- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03762408
Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis. (ENKORE)
Comparative Study of the Efficacy and Safety of an Intra-articular Injection of ENKO 1 vs Durolane in Patients With Symptomatic Osteoarthritis of the Knee.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
A Coruña, Spain, 15009
- Instituto Médico Arriaza
-
Barcelona, Spain, 08003
- Hospital Del Mar
-
Barcelona, Spain, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spain, 08022
- Instituto POAL del Reumatología
-
Barcelona, Spain, 08035
- Hospital Sant Rafael
-
Madrid, Spain, 28027
- BiClinic
-
Málaga, Spain, 29004
- AMS Centro Médico del Ejercicio
-
Sevilla, Spain, 41001
- Clínica ISMEC
-
Valencia, Spain, 46015
- Clínica Gastaldi
-
Valladolid, Spain, 47004
- Clínica Traumatológica Dr. Baró
-
Vitoria Gasteiz, Spain, 01008
- Hospital Vithas San Jose
-
-
Barceloma
-
Esplugues De Llobregat, Barceloma, Spain, 08950
- Clinica Diagonal
-
-
Barcelona
-
Esplugues De Llobregat, Barcelona, Spain, 08950
- Consell calatà de l'Esport
-
Terrassa, Barcelona, Spain, 08227
- Consorci Sanitari de Terrassa
-
-
Cádiz
-
Chiclana de la Frontera, Cádiz, Spain, 11139
- Clínica Novo Sancti Petri
-
-
Madrid
-
Torrejón De Ardoz, Madrid, Spain, 28002
- Clínica IQTRA
-
Torrelodones, Madrid, Spain, 28250
- Hospital de Torrelodones
-
-
Málaga
-
Mijas Costa, Málaga, Spain, 29651
- Clínica Dr. Casermeiro
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Medial femorotibial compartment knee OA.
- Fulfilment of ACR criteria for knee OA (knee pain + grinding + stiffness in the morning < 30 minutes).
- Patients with a clinical course of disease longer than 6 months.
- Global pain score greater than 60 mm on a 0-100 mm VAS on the knee under study.
- Grade II or III according to the Kellgren and Lawrence classification system for the knee under study (on a posteroanterior X-ray performed under weight-bearing and for 6 months before randomisation).
- Patients taking analgesics for at least 3 months before randomisation and whom are dissatisfied with their current therapy.
- Patients who have given their consent in writing to take part in the study.
- Woman of childbearing age must take a urine pregnancy test which must be negative at the randomisation visit and be currently using an effective contraceptive method for at least 2 menstrual cycles (oral contraceptives, intrauterine device, tubal ligation or other effective procedures).
Exclusion Criteria:
- Isolated symptomatic patellofemoral osteoarthritis.
- Microcrystalline osteoarthritis.
- Prosthesis in knee under study.
- Joint lavage or arthroscopy or any surgery on the knee under study in the 6 months before randomisation.
- Paget's disease of bone, chondromatosis or villonodular sinovitis.
- Inflammatory, infectious or metabolic arthritis (rheumatoid arthritis, spondyloarthropathy or connective tissue diseases).
- Haemochromatosis, ochronosis or haemophilia.
- History of diseases that the investigator considers likely to interfere with the functional disability assessment.
- Knee surgery planned during the study period.
Other disease-related criteria:
- BMI greater than or equal to 30.
- Immunodeficiency or a serious or progressive disease (heart, lung, liver, kidney, haematological, neoplastic or infectious disease).
- Skin diseases or infections in the area of the injection site.
- Previous history of venous thromboembolism (including pulmonary embolism) or high risk of venous thromboembolism.
- Venous or lymphatic stasis of the leg under study.
- Severe acute or chronic disease that the investigator considers incompatible with the conduct of the study.
- Disease that the investigator considers likely to interfere with the study results or to expose the patient to an additional risk.
- Alcohol or drug abuse or dependence.
Previous or concomitant treatment-related criteria:
- Patients who have taken a SYSADOA, SERM or a drug/dietary supplement containing glucosamine, chondroitin sulfate, diacerein or avocado-soybean extracts in the 3 months before randomisation
- Patients who have taken paracetamol in the 24 hours before randomisation or any other symptomatic analgesic drug, including NSAIDs (except aspirin up to 325 mg/day for cardiovascular prophylaxis), in the 48 hours before randomisation
- Patients who have received any corticosteroid treatment by any route of administration (other than inhalers or the ocular or auricular routes) in the month before randomisation
- Patients who have received an intra-articular steroid injection in the knee under study in the month before randomisation or patients who have received intra-articular hyaluronic acid in the target knee in the 6 months before randomisation
- Patients who have received any local or topical treatment on the target knee in the 2 weeks before randomisation
Criteria related to concomitant medication:
- Hypersensitivity to paracetamol or NSAIDs
Study product-related criteria:
- Known allergy to the study treatments or to any of its ingredients.
Other criteria:
- Patients likely to be unable to comply with the protocol instructions and/or treatment, in the investigator's opinion
- Patients who have taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of randomisation
- Patients linguistically or mentally incapable of understanding the nature, objectives and possible consequences of the study; or who refuse to be subject to its limitations
- Patients who are family or colleagues (secretary, nurse, technician, etc.) of the investigator.
- Women: pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ENKO 1
ENKO 1 administered by single intra-articular injection.
|
50 mg of HA/ 50 mg of CS in 5 ml
|
Active Comparator: Durolane
Durolane administered by single intra-articular injection.
|
60 mg HA crosslinked in 3 ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Relief
Time Frame: Change from baseline pain relief at 6 months.
|
Assessed using VAS (Visual Analogue Scale) Huskisson 0-100mm Pain relief scored on a scale of 0 to 10. 0 means No pain and 10 means worst possible pain. |
Change from baseline pain relief at 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Relief
Time Frame: 0, 1, 6 and 12 weeks.
|
Assessed using VAS (Visual Analogue Scale) Huskisson 0-100mm Pain relief scored on a scale of 0 to 10. 0 means No pain and 10 means Worst possible pain. |
0, 1, 6 and 12 weeks.
|
Evaluation of functional WESTERN ONTARIO AND MCMASTER OSTEOARTHRITIS INDEX (WOMAC) index score (Pain subscale)
Time Frame: -7, 0, 1, 6, 12 and 24 weeks.
|
Validated questionnaire for patients with osteoarthritis of the knee. 5 items: during walking, using stairs, in bed, sitting or lying, and standing upright. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. |
-7, 0, 1, 6, 12 and 24 weeks.
|
Evaluation of functional WESTERN ONTARIO AND MCMASTER OSTEOARTHRITIS INDEX (WOMAC) index score (Stiffness subscale)
Time Frame: -7, 0, 1, 6, 12 and 24 weeks.
|
Validated questionnaire for patients with osteoarthritis of the knee. 2 items: after first waking and later in the day. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. |
-7, 0, 1, 6, 12 and 24 weeks.
|
Evaluation of functional WESTERN ONTARIO AND MCMASTER OSTEOARTHRITIS INDEX (WOMAC) index score (Functional capacity subscale)
Time Frame: -7, 0, 1, 6, 12 and 24 weeks.
|
Validated questionnaire for patients with osteoarthritis of the knee. 17 items): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. |
-7, 0, 1, 6, 12 and 24 weeks.
|
Evaluation of percentage of patients who respond to treatment
Time Frame: 0, 1, 6, 12 and 24 weeks.
|
Evaluation of percentage of patients who respond to treatment according to the OMERACT-OARSI criteria.
|
0, 1, 6, 12 and 24 weeks.
|
Global evaluation of the activity of the disease and of the respond to treatment by patient.
Time Frame: 0, 1, 6, 12 and 24 weeks.
|
Global evaluation of the activity of disease by the patient (VAS (Visual Analogue Scale) from 0-100mm). Scale from 0 to 10, which correspond to: Mild (0-2), Moderate (3-7) and Intense (8-10). where 0 is better outcome and 10 is the worst outcome. |
0, 1, 6, 12 and 24 weeks.
|
Evaluation of Health status of patients
Time Frame: 0, 1, 6, 12 and 24 weeks.
|
Evaluation of Health status by quality of life questionnaire 12-Item Short Form Survey (SF-12). It consists of 12 items from the 8 dimensions of the SF-36 Physical Function, Social Function, Physical Role, Emotional Role, Mental Health, Vitality, Body Pain, General Health and evaluate intensity and frequency of each item. Scale ranges: Minimum 12 and maximum 60 scores. When 12 means better and 60 is the worse outcome. |
0, 1, 6, 12 and 24 weeks.
|
Evaluation of concomitant medication intake
Time Frame: -7, 0, 1, 6, 12 and 24 weeks.
|
Daily intake of Paracetamol (maximum 3g/day)
|
-7, 0, 1, 6, 12 and 24 weeks.
|
Evaluation of synovitis
Time Frame: -7, 0, 1, 6, 12 and 24 weeks.
|
Clinical valoration of synovial joint swelling.
|
-7, 0, 1, 6, 12 and 24 weeks.
|
Biomarkers
Time Frame: -7 and 12 weeks
|
Blood sample analysis of serum soluble biomarkers according to current validation by THE BIOMARKERS CONSORTIUM. Pre-selected biomarkers: Concentration of Serum CTXI, Serum NTXI, Serum-HA, Serum-PIIANP and Serum CTXII. |
-7 and 12 weeks
|
Adverse events
Time Frame: 0, 1, 6, 12 and 24 weeks.
|
Number of Participants with any Adverse event.
|
0, 1, 6, 12 and 24 weeks.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Luisa Varela, Ph, MSc, OPKO Health, Inc.
- Principal Investigator: Jordi Monfort, MD, PhD, Hospital Del Mar
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPK-ENK-2017-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
-
National Yang Ming UniversityFar Eastern Memorial HospitalCompletedMedial Knee OsteoarthritisTaiwan
-
Hanlim Pharm. Co., Ltd.CompletedKnee OsteoarthritisKorea, Republic of
Clinical Trials on ENKO 1
-
Orasis Pharmaceuticals Ltd.Completed
-
University of Sao Paulo General HospitalCompleted
-
University of ThessalyCompleted
-
Chulalongkorn UniversityCompletedAllergic RhinitisThailand
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth II Health Sciences Centre and other collaboratorsCompletedHypertriglyceridemiaCanada
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); United States Department... and other collaboratorsCompleted
-
Yonsei UniversityCompletedObese Patients, One Lung VentilationKorea, Republic of
-
Queen Margaret UniversityNHS LothianTerminated
-
Janssen Research & Development, LLCCompletedRelapsed or Refractory Hodgkin LymphomaFrance, Germany